327 related articles for article (PubMed ID: 23949878)
1. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.
Ballehaninna UK; Chamberlain RS
Tumour Biol; 2013 Dec; 34(6):3279-92. PubMed ID: 23949878
[TBL] [Abstract][Full Text] [Related]
2. Progress on molecular markers of pancreatic cancer.
Grote T; Logsdon CD
Curr Opin Gastroenterol; 2007 Sep; 23(5):508-14. PubMed ID: 17762556
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.
Goonetilleke KS; Siriwardena AK
Eur J Surg Oncol; 2007 Apr; 33(3):266-70. PubMed ID: 17097848
[TBL] [Abstract][Full Text] [Related]
4. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
Chang JC; Kundranda M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
[TBL] [Abstract][Full Text] [Related]
5. Novel serum tumor marker, RCAS1, in pancreatic diseases.
Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
[TBL] [Abstract][Full Text] [Related]
6. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.
Tonack S; Jenkinson C; Cox T; Elliott V; Jenkins RE; Kitteringham NR; Greenhalf W; Shaw V; Michalski CW; Friess H; Neoptolemos JP; Costello E
Br J Cancer; 2013 May; 108(9):1846-53. PubMed ID: 23579209
[TBL] [Abstract][Full Text] [Related]
7. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
8. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma.
Kriz D; Ansari D; Andersson R
Clin Transl Oncol; 2020 Dec; 22(12):2170-2174. PubMed ID: 32447642
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
Satake K; Takeuchi T
Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
11. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9: Biochemical and Clinical Aspects.
Scarà S; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
[TBL] [Abstract][Full Text] [Related]
13. Serum APRIL, a potential tumor marker in pancreatic cancer.
Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
[TBL] [Abstract][Full Text] [Related]
14. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
[TBL] [Abstract][Full Text] [Related]
15. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art.
Plebani M; Basso D; Panozzo MP; Fogar P; Del Favero G; Naccarato R
Int J Biol Markers; 1995; 10(4):189-99. PubMed ID: 8750644
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
19. [Tumor markers in the diagnosis of pancreatic cancer].
Cappelli G; Paladini S; D'Agata A
Tumori; 1999; 85(1 Suppl 1):S19-21. PubMed ID: 10235075
[TBL] [Abstract][Full Text] [Related]
20. Early detection of pancreatic carcinoma.
Rosty C; Goggins M
Hematol Oncol Clin North Am; 2002 Feb; 16(1):37-52. PubMed ID: 12063828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
